Next-generation diaper technology with targeted skin-protective active release
Innovative diaper technology using glucan particle encapsulation for moisture-activated release of skin-protective actives, enhancing comfort and protection for infants. Incorporates soothing, anti-inflammatory, and protective compounds to calm irritation and reinforce the skin barrier.
Overview
This next-generation diaper technology transforms traditional diapers into smart, responsive platforms that enhance skin protection and comfort for infants. By leveraging glucan particle (GP) encapsulation, the technology enables the moisture-activated release of skin-protective actives (SPAs). These actives include soothing and anti-inflammatory compounds like panthenol and zinc oxide that help calm irritation and support skin recovery, as well as protective agents like magnesium ascorbyl phosphate and peptides that reinforce the skin barrier. Additionally, fragrances and odor-neutralizing compounds can be incorporated to effectively manage diaper odor.
Technical specifications
- Moisture-activated release: The GP encapsulation allows for the controlled release of SPAs in response to moisture, ensuring timely delivery.
- Versatile SPA incorporation: Capable of embedding both hydrophilic and hydrophobic SPAs, tailored to specific needs.
- Anti-inflammatory benefits: The β-glucan component offers inherent anti-inflammatory and immunomodulatory effects, supporting skin healing.
- Customizable formulations: Diaper formulations can be optimized for different infant age groups and skin needs.
Technology readiness level
Currently at Technology Readiness Level 3, this technology is in the early stages of development, with ongoing efforts to prepare GP encapsulated zinc oxide formulations and test their release kinetics. Collaboration with industry partners will facilitate further integration and characterization of these actives within diaper fabrics.
About University of Massachusetts Medical School
A public academic health sciences center within the University of Massachusetts system, it combines medical education, graduate training, and patient care with a strong research enterprise. Close integration with a major hospital system enables access to diverse patient populations, clinical data, and translational infrastructure, supporting industry‑sponsored studies and real‑world evaluation. Co‑located research core facilities and centralized contracting, IRB, and compliance support streamline collaboration, from early discovery through multicenter trials. The institution attracts significant NIH funding and competitive awards from other federal agencies and foundations. A dedicated technology transfer office manages IP, material transfer and licensing, and supports startup formation and corporate research agreements.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.